RA
LJPC

Royce & Associates’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Royce & Associates’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-60,000
Closed -$1.11M – 1384
2014
Q4 		$1.11M Buy
+60,000
New +$712K ﹤0.01% 1058

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Royce & Associates's LJPC Position: Q1 2015 in Review

Royce & Associates sold out of La Jolla Pharmaceutical Company (LJPC) in Q1 2015, closing a stake of 60,000 shares — an estimated $1.11M sold.

Royce & Associates first reported a position in LJPC in Q4 2014 and held it in 1 quarter. The position peaked at $1.11M in Q4 2014. 40 funds tracked by Wall St. Rank hold LJPC as of Q1 2015.

  • Royce & Associates reported no remaining La Jolla Pharmaceutical Company position as of Q1 2015 after selling out during the quarter.
  • Royce & Associates sold 60,000 La Jolla Pharmaceutical Company shares in Q1 2015, an estimated $1.11M.
  • Royce & Associates first reported a position in La Jolla Pharmaceutical Company in Q4 2014 and held it in 1 quarter.
  • Royce & Associates's La Jolla Pharmaceutical Company position peaked at $1.11M in Q4 2014.
  • 40 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q1 2015.

Based on Royce & Associates's 13F filing for Q1 2015, filed 13 May 2015.